Company: BIAF
Filing Date: 2025-06-02
Form Type: DEF 14A
Source: 0001641172-25-013280
Chunk: 45

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-02
Form: DEF 14A
Chunk 45
---
 of the number of shares of our Common Stock outstanding immediately after giving effect to the
exercise, as such percentage ownership is determined in accordance with the terms of the New Warrants. However, any holder may increase
or decrease such percentage, provided that any increase will not be effective until the 61st day after such election.

In the event
of a Fundamental Transaction (as such term is defined in the New Warrant), then the successor entity will succeed to, and be substituted
for the Company, and may exercise every right and power that the Company may exercise and will assume all of its obligations under the
New Warrants with the same effect as if such successor entity had been named in the warrant itself. If holders of Common Stock are given
a choice as to the securities, cash, or property to be received in a Fundamental Transaction, then the holder shall be given the same
choice as to the consideration it receives upon any exercise of the New Warrants following such Fundamental Transaction. In addition,
the successor entity, at the request of holders of New Warrants, will be obligated to purchase any unexercised portion of the New Warrants
in accordance with the terms thereof. Notwithstanding the foregoing, in the event of a Fundamental Transaction, the holders of the New
Warrants have the right to require the Company or a successor entity to redeem the New Warrants for cash in the amount of the Black Scholes
Value (as defined in the New Warrant) of the unexercised portion of the New Warrants concurrently with or within 30 days following the
consummation of a Fundamental Transaction. However, in the event of a Fundamental Transaction which is not in our control, including
a Fundamental Transaction not approved by the Company’s Board, the holders of the New Warrants will only be entitled to receive
from the Company or its successor entity, as of the date of consummation of such Fundamental Transaction, the same type or form of consideration
(and in the same proportion), at the Black-Scholes Value of the unexercised portion of the New Warrant that is being offered and paid
to the holders of Common Stock in connection with the Fundamental Transaction, whether that consideration is in the form of cash, stock,
or any combination of cash and stock, or whether the holders of our Common Stock are given the choice to receive alternative forms
of consideration in connection with the Fundamental Transaction.

| 24 |

The Advisor
Warrants have substantially the same terms as the New Warrants